On Thursday, December 12th, Merriman Capital, Inc. will host an investor call for Pressure BioSciences, Inc. (PBIO) at 4:30 p.m. EST. Investors and any other interested parties should dial into this call for an update on PBIO’s recent achievements, such as the Company’s record revenue in the third quarter 2013, and forthcoming milestones. A Q&A session will also be available following the call. Pressure BioSciences’ CEO Richard T. Schumacher, Board Chairman Jeffrey N. Peterson, and other board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will join in the Q&A.
Conference Call Details
Format: Conference Call and Webcast with PowerPoint presentation
Date: Thursday, December 12, 2013
Time: 4:30 PM Eastern Standard Time (EST)
Dial-in Numbers:
(800) 875-3456 (U.S.)
(800) 648-0973 (Canada)
(302) 607-2001 (International)
Passcode: VS87265
Conference ID: 865561
Click here (http://www.join.me/pbio.investormeeting.M1) to view webcast and enter the call-in number above for audio.
The PowerPoint and a replay of the call will be available on PBIO’s website.
Why Pressure BioSciences?
Pressure BioSciences, Inc. (PBIO-OTC), one of the newest companies in our coverage universe, holds exciting new technologies for life science research—technologies that could help advance the work being done in tens of thousands of laboratories worldwide. The Company’s pressure cycling technology (PCT) platform, which is able to apply and release high levels of hydrostatic pressure in a safe and controlled manner, aids researchers and scientists by giving them the laboratory equipment needed to improve the processing of samples—which ultimately can lead to higher-quality research in critical fields like testing cancer therapies, creating new vaccines, and even faster and more accurate DNA analysis for things like processing rape kits. As an indication of the competitive advantage in research that Pressure BioSciences’ products can offer, to the Company’s knowledge, PCT has been shown to be the only technology able to completely kill anthrax while still leaving the sample in a testable state.
Having demonstrated the utility of its equipment through roughly 235 installations in 150 marquee laboratories around the world, the industry is starting to take notice of the small-cap Pressure BioSciences, and with good reason. For the third quarter 2013, Pressure BioSciences reported all-time-high quarterly revenue of over $420,000, coming primarily from increased product and services sales. YTD, ended September 30, 2013, Pressure BioSciences reported revenues of approximately $1.15 million, a 12% increase over the same period in 2012.
For further details on PBIO’s Q3 and year-to-date results, forecasted Q4 results, and pipeline of innovative new products, read our November 19th article here.
* * * * * * * * * * *
Visit PBIO's Corporate Profile for access to
the latest research, news, and stock information
on Pressure BioSciences, Inc.
* * * * * * * * * * *